More importantly, our data from HCC model mice revealed that combining an HKDC1 siRNA nanotherapy with anti-PD-1/PD-L1 treatment could enhance antitumor response without exacerbating irAEs, after adjusting for confounding factors, such as survival time, body weight, HCT, HGB and blood glucose level. The gene discussed is HKDC1; the disease is hepatocellular carcinoma.